Loading cancer entity…
Loading cancer entity…
Clinical trials
3,221 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (571)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03767348 | Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)(IGNYTE) | active not recruiting | Phase 2 | 340 | Replimune, Inc.INDUSTRY | 5 | Feb 13, 2026 | clinicaltrials |
| NCT07406724 | HS-IT101 Injection Versus Chemotherapy in the Treatment of Advanced Melanoma | not yet recruiting | Phase 2 | 90 | Qingdao Sino-Cell Biomedicine Co., Ltd.INDUSTRY | 0 | Feb 12, 2026 | clinicaltrials |
| NCT06190951 | A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma | active not recruiting | Phase 2 | 151 | Regeneron PharmaceuticalsINDUSTRY | 8 | Feb 10, 2026 | clinicaltrials |
| NCT04478279 | A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 125 | Sapience TherapeuticsINDUSTRY | 2 | Feb 9, 2026 | clinicaltrials |
| NCT05418972 | A Phase 2 Clinical Trial of Neoadjuvant Relatlimab and Nivolumab in High Risk, Clinical Stage II Cutaneous Melanoma(Neo ReNi II) | active not recruiting | Phase 2 | 20 | Melanoma Institute AustraliaOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT03340129 | Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study)(ABC-X) | recruiting | Phase 2 | 218 | Melanoma Institute AustraliaOTHER | 2 | Feb 2, 2026 | clinicaltrials |
| NCT04645680 | Diet and Immune Effects Trial: DIET- A Randomized Double Blinded Dietary Intervention Study in Patients With Metastatic Melanoma Receiving Immunotherapy(DIET) | active not recruiting | Phase 2 | 50 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 30, 2026 | clinicaltrials |
| NCT03474497 | UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade | active not recruiting | Phase 1 / Phase 2 | 18 | Megan Daly, MDOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT07376317 | Optimization of Immunotherapy Treatment for Advanced Melanoma in the Context of the Public Brazilian Health System (OTIMAS)(OTIMAS) | active not recruiting | Phase 2 | 29 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT07371663 | An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 266 | Beijing Tide Pharmaceutical Co., LtdINDUSTRY | 1 | Jan 28, 2026 | clinicaltrials |
| NCT05529316 | A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma | active not recruiting | Phase 2 | 150 | Agenus Inc.INDUSTRY | 10 | Jan 16, 2026 | clinicaltrials |
| NCT06717126 | A Randomised Phase II Study of Roginolisib in Patients With Advanced/Metastatic Uveal Melanoma(OCULE-01) | active not recruiting | Phase 2 | 85 | iOncturaINDUSTRY | 3 | Jan 16, 2026 | clinicaltrials |
| NCT07347444 | Iparomlimab and Tuvoraleimab Injection in Combination With Bevacizumab, Albumin-bound Paclitaxel, and Carboplatin as First- or Second-line Treatment for Patients With Advanced Acral and Mucosal Melanoma | not yet recruiting | Phase 2 | 48 | Fudan UniversityOTHER | 1 | Jan 16, 2026 | clinicaltrials |
| NCT03228667 | QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors | active not recruiting | Phase 2 | 40 | ImmunityBio, Inc.INDUSTRY | 1 | Jan 14, 2026 | clinicaltrials |
| NCT07336979 | Paclitaxel Polymersomes + Carboplatin + Adebelimab: Neoadjuvant Phase Ⅱ Single-Arm Study for Resectable Mucosal Melanoma | recruiting | Phase 2 | 32 | Sun Yat-sen UniversityOTHER | 1 | Jan 13, 2026 | clinicaltrials |
| NCT03829254 | A Safety, Pharmacokinetic and Clinical Activity Study of NUC-7738 in Patients With Advanced Solid Tumours and Lymphoma | recruiting | Phase 1 / Phase 2 | 135 | NuCana plcOTHER | 1 | Jan 12, 2026 | clinicaltrials |
| NCT05428007 | Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma | recruiting | Phase 2 | 105 | NYU Langone HealthOTHER | 1 | Jan 5, 2026 | clinicaltrials |
| NCT07310758 | Contrast-enhanced Ultrasound for Sentinel Node Detection | recruiting | Phase 2 / Phase 3 | 91 | The Netherlands Cancer InstituteOTHER | 1 | Dec 30, 2025 | clinicaltrials |
| NCT04079166 | SCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SCOPE Study) | active not recruiting | Phase 2 | 173 | Scancell LtdINDUSTRY | 1 | Dec 19, 2025 | clinicaltrials |
| NCT02374242 | Anti-PD 1 Brain Collaboration for Patients With Melanoma Brain Metastases(ABC) | active not recruiting | Phase 2 | 76 | Melanoma Institute AustraliaOTHER | 1 | Dec 10, 2025 | clinicaltrials |
| NCT06121180 | Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma | recruiting | Phase 2 | 32 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT06194929 | Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma(DETERMINE) | recruiting | Phase 1 / Phase 2 | 33 | University of UtahOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT07070518 | Study of GV20-0251 in Participants With Solid Tumor Malignancies | recruiting | Phase 1 / Phase 2 | 350 | GV20 TherapeuticsINDUSTRY | 1 | Dec 3, 2025 | clinicaltrials |
| NCT07136181 | Evaluation of the Safety, Efficacy, and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma(NBM-BMX-UM) | recruiting | Phase 1 / Phase 2 | 36 | Novelwise Pharmaceutical CorporationINDUSTRY | 1 | Nov 28, 2025 | clinicaltrials |
| NCT05768178 | DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT05770102 | DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT05770544 | DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers.(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT06784648 | Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma | active not recruiting | Phase 1 / Phase 2 | 35 | BioInvent International ABINDUSTRY | 3 | Nov 19, 2025 | clinicaltrials |
| NCT07236528 | Combination of Carilizumab, Apatinib, and Radiotherapy for Advanced Mucosal Melanoma | not yet recruiting | Phase 2 | 30 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 0 | Nov 19, 2025 | clinicaltrials |
| NCT07237100 | Mirdametinib in Patients With Advanced NF1-mutant Melanoma | recruiting | Phase 2 | 10 | Kevin Kim, MDOTHER | 1 | Nov 19, 2025 | clinicaltrials |
| NCT06521567 | A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer | active not recruiting | Phase 1 / Phase 2 | 83 | GlaxoSmithKlineINDUSTRY | 6 | Nov 12, 2025 | clinicaltrials |
| NCT07155317 | Time-of-Day Specified Immunotherapy for Advanced Melanoma, The TIME Trial | recruiting | Phase 2 | 99 | Emory UniversityOTHER | 1 | Nov 12, 2025 | clinicaltrials |
| NCT04074967 | Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab | active not recruiting | Phase 1 / Phase 2 | 70 | Dan ZandbergOTHER | 1 | Nov 6, 2025 | clinicaltrials |
| NCT04139902 | Neoadjuvant PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor Cobolimab (TSR-022) and PD-1 Inhibitor Dostarlimab (TSR-042) in Melanoma | active not recruiting | Phase 2 | 48 | Diwakar DavarOTHER | 1 | Oct 15, 2025 | clinicaltrials |
| NCT07215182 | [68Ga]Ga-FAPI Total Body PET/CT for Better and Faster Imaging in Cancer(BEFAST) | recruiting | Phase 2 | 20 | Barbara Malene FischerOTHER | 1 | Oct 10, 2025 | clinicaltrials |
| NCT04370587 | A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 30 | ImmVira Pharma Co. LtdINDUSTRY | 2 | Oct 8, 2025 | clinicaltrials |
| NCT00722228 | Autologous and Allogeneic Whole Cell Cancer Vaccine for Metastatic Tumors | recruiting | Phase 1 / Phase 2 | 50 | Hadassah Medical OrganizationOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT01898039 | Modified Vaccine for High Risk or Low Residual Melanoma Patients | recruiting | Phase 1 / Phase 2 | 50 | Hadassah Medical OrganizationOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT05296564 | Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers | recruiting | Phase 1 / Phase 2 | 3 | Hadassah Medical OrganizationOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT05309421 | A Single Arm Trial Evaluating the Efficacy and Safety of EVX-01 in Combination With Pembrolizumab in Adults With Unresectable or Metastatic Melanoma | active not recruiting | Phase 2 | 17 | Evaxion Biotech A/SINDUSTRY | 2 | Sep 22, 2025 | clinicaltrials |
| NCT05893654 | Melphalan Chemoreduction for Ocular Melanoma(MELCOM) | enrolling by invitation | Phase 1 / Phase 2 | 10 | Hospital das Clínicas de Ribeirão PretoOTHER | 1 | Sep 15, 2025 | clinicaltrials |
| NCT03470922 | A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma(RELATIVITY-047) | active not recruiting | Phase 2 / Phase 3 | 714 | Bristol-Myers SquibbINDUSTRY | 25 | Sep 9, 2025 | clinicaltrials |
| NCT04283890 | PHP and Immunotherapy in Metastasized UM(CHOPIN) | active not recruiting | Phase 1 / Phase 2 | 83 | Leiden University Medical CenterOTHER | 1 | Sep 9, 2025 | clinicaltrials |
| NCT06209580 | AMT-253 in Patients With Advanced Solid Tumours | recruiting | Phase 1 / Phase 2 | 96 | Multitude Therapeutics Inc.INDUSTRY | 1 | Sep 5, 2025 | clinicaltrials |
| NCT05585320 | A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 209 | Immuneering CorporationINDUSTRY | 1 | Sep 2, 2025 | clinicaltrials |
| NCT06359860 | A Study of ST-1898 for Unresectable or Metastatic Melanoma | recruiting | Phase 1 / Phase 2 | 64 | Beijing Scitech-Mq Pharmaceuticals LimitedINDUSTRY | 1 | Aug 24, 2025 | clinicaltrials |
| NCT07130032 | Efficacy And Safety Of Anti-PD-1/PD-L1 Antibodies In Combination With Bevacizumab And Metronomic Cyclophosphamide In Patients With Non-Small Cell Lung Cancer And Cutaneous Melanoma Previously Treated With Immune Checkpoint Blockade(reICB) | recruiting | Phase 2 | 90 | EuroCityClinic LLCNETWORK | 1 | Aug 19, 2025 | clinicaltrials |
| NCT05057013 | A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours | active not recruiting | Phase 1 / Phase 2 | 81 | Cancer Research UKOTHER | 1 | Aug 11, 2025 | clinicaltrials |
| NCT03611868 | A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 230 | Ascentage Pharma Group Inc.INDUSTRY | 2 | Aug 7, 2025 | clinicaltrials |
| NCT03235245 | Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib(EBIN) | active not recruiting | Phase 2 | 271 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 9 | Aug 1, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Feb 13, 2026source: clinicaltrials